Table 4 Case series of recurred mCNV patients with neovascular signal around PSV
Patient No | Sex | Age (years) | Affected eye | Baseline BCVA | CNV patterns | Drug | No. of initial injections | First recurrence time (months after diagnosis)/types | PSV around recurrent CNV | BCVA at 12 months |
|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 57 | Right | 20/100 | “Medusa” | Ranibizumab | 1 | 5/Reactivation | Yes | 20/67 |
2 | F | 57 | Left | 20/40 | “Indistinct network” | Ranibizumab | 1 | 14/Reactivation | Yes | 20/67 |
3 | F | 85 | Left | 20/100 | “Seafan” | Conbercept | 3 | 4/New CNV | Yes | 20/200 |
4 | M | 36 | Left | 20/2000 | “Indistinct network” | Conbercept | 3 | 11/Reactivation | Yes | 20/50 |
5 | F | 64 | Right | 20/200 | “Medusa” | Conbercept | 1 | 5/Reactivation | Yes | 20/33 |
6 | F | 40 | Right | 20/40 | “Medusa” | Conbercept | 5 | 38/Enlargement | Yes | 20/30 |
7 | F | 60 | Left | 20/200 | “Medusa” | Conbercept | 3 | 47/Enlargement | Yes | 20/100 |
8 | M | 48 | Left | 20/100 | “Medusa” | Ranibizumab | 2 | 21/New CNV | No | 20/33 |
9 | F | 62 | Right | 20/125 | “Medusa” | Conbercept | 2 | 7/Reactivation | Yes | 20/40 |
10 | F | 71 | Right | 20/400 | “Seafan” | Conbercept | 2 | 36/Reactivation | No | 20/50 |
11 | F | 54 | Left | 20/400 | “Medusa” | Conbercept | 3 | 21/Enlargement | Yes | 20/2000 |
12 | F | 53 | Right | 20/50 | “Seafan” | Ranibizumab | 3 | 4/Reactivation | No | 20/40 |
13 | F | 26 | Right | 20/40 | “Indistinct network” | Ranibizumab | 1 | 44/New CNV | No | 20/25 |